scholarly journals Intravesical Treatment Modalities in Bladder Cancer: Current and Future Perspectives

10.5772/66305 ◽  
2017 ◽  
Author(s):  
Turgay Turan ◽  
Bulent Erol ◽  
Asif Yildirim ◽  
Turhan Caskurlu
Keyword(s):  
Bladder Cancer ◽  
Treatment Modalities ◽  
Future Perspectives ◽  
Intravesical Treatment

Hypoxia and its Modification in Bladder Cancer: Current and Future Perspectives

2021 ◽  
Author(s):  
T. Lodhi ◽  
Y.P. Song ◽  
C. West ◽  
P. Hoskin ◽  
A. Choudhury
Keyword(s):  
Bladder Cancer ◽  
Future Perspectives

scholarly journals Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives

2021 ◽  
Vol 22 (13) ◽  
pp. 7201
Author(s):  
In-Ho Kim ◽  
Hyo-Jin Lee
Keyword(s):  
Bladder Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Systemic Treatment ◽  
Checkpoint Inhibitors ◽  
Invasive Bladder Cancer ◽  
Current Evidence ◽  
Future Perspectives ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Radical cystectomy is the primary treatment for muscle-invasive bladder cancer; however, approximately 50% of patients develop metastatic disease within 2 years of diagnosis, which results in dismal prognosis. Therefore, systemic treatment is important to improve the prognosis of muscle-invasive bladder cancer. Currently, several guidelines recommend cisplatin-based neoadjuvant chemotherapy before radical cystectomy, and adjuvant chemotherapy is recommended in patients who have not received neoadjuvant chemotherapy. Immune checkpoint inhibitors have recently become the standard treatment option for metastatic urothelial carcinoma. Owing to their clinical benefits, several immune checkpoint inhibitors, with or without other agents (including other immunotherapy, cytotoxic chemotherapy, and emerging agents such as antibody drug conjugates), are being extensively investigated in perioperative settings. Several studies for perioperative immunotherapy have shown that immune checkpoint inhibitors have promising efficacy with relatively low toxicity, and have explored the predictive molecular biomarkers. Herein, we review the current evidence and discuss the future perspectives of perioperative systemic treatment for muscle-invasive bladder cancer.

Intravesical treatment of bladder cancer with recombinant human interferon-β

1989 ◽  
Vol 30 (2) ◽  
pp. 81-85 ◽  
Author(s):  
Tadao Niijima ◽  
Takashi Umeda ◽  
Manabu Kuriyama ◽  
Hiroyuki Ohmori ◽  
Yohsuke Matsumura ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Human Interferon ◽  
Interferon Β ◽  
Intravesical Treatment

Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities

2021 ◽  
Vol 158 ◽  
pp. 105648
Author(s):  
Nada M. El Hoffy ◽  
Engy A. Abdel Azim ◽  
Rania M. Hathout ◽  
Marwa A. Fouly ◽  
Seham A. Elkheshen
Keyword(s):  
Treatment Modalities ◽  
Future Perspectives
Sign in / Sign up

Export Citation Format

Share Document